Subscribe

Essex Bio-Technology Limited (1061.HK)

HKD2.80 +0.05 (+1.82%)
CN HKSE Healthcare Drug Manufacturers - Specialty & Generic
Address No. 88 Keji 6th Road
Zhuhai, CN
CEO Hian Leng Ngiam
Website essexbio.com
IPO 2001-06-27
ISIN KYG312371035

Explore sections of this company profile

Description

Essex Bio-Technology Limited operates as an investment holding company, specializing in the development, manufacturing, distribution, and sale of biopharmaceutical products. Its business activities extend across the People's Republic of China and into international territories. The company organizes its operations into two primary segments: Ophthalmic Products and Surgical Products. A significant focus of its research and development is on basic fibroblast growth factor (bFGF) products, which are utilized to promote cellular proliferation, differentiation, and migration. Its ophthalmic offerings include the Beifushu series, comprising eye drops, eye gel, and unit-dose eye drops. Other eye care solutions feature Tobramycin eye drops, Levofloxacin eye drops, Sodium Hyaluronate eye drops, and Iodized Lecithin Capsules. For surgical and wound care needs, the company supplies Beifuji sprays and lyophilized powder, along with Beifuxin gels. These are applied in cases of burns, scalds, acute wounds, surgical incisions, chronic wounds, and skin grafting, among other uses. In addition to its proprietary innovations, Essex Bio-Technology distributes ophthalmic and surgical products sourced from third-party manufacturers. Its diverse product portfolio also encompasses Carisolv dental caries removal gel and Yi Xue An Granules. The company holds licensing agreements with both Mitotech S.A. and Mitotech LLC. Founded in 1990, Essex Bio-Technology Limited maintains its headquarters in Zhuhai, China.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
HKD2.80 +0.05 (+1.82%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
498.6K
Beta
-0.05
Float Shares
405.73M
Free Float %
71.6%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+3.75% +4.47% -6.17% -27.62% -27.79% -19.36% -41.76% -10.85% -42.86% -24.38% +210.20%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
2.80
DCF (Unlevered) 7.90 +182.0%
DCF (Levered) 10.72 +282.9%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 100% Bullish
Rating 2026-05 Change
Strong Buy 0 0
Buy 1 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
2.95
Grey zone
Piotroski F-Score
7 / 9
Strong
MOAT Score
6 / 10
Developing
Composite Rating
A+
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
3 / 5
Medium
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers ★ Strong MOAT
  • ✓
    Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%
    +8.6% ★ Q4'25: +16.1% (vs Q4'23)
  • ✓
    EPS growth Drug Manufacturers - Specialty & Generic: +16.5%
    +5.7% Q4'25: +50.0% (vs Q4'23)
  • ✓
    FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%
    +11.8% Q4'25: +8.5% (vs Q4'23)
  • ✓
    EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%
    +23.0% ★ Q4'25: +21.9% (vs Q4'23)
  • ✓
    ROIC Drug Manufacturers - Specialty & Generic: +6.5%
    +16.2% ★ Q4'25: +30.5% (vs Q4'23)
  • ✓
    Share dilution Drug Manufacturers - Specialty & Generic: +0.0%
    -2.6% ★ Q4'25: -4.5% (vs Q4'23)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×
    0.74× ★ Q4'25: 0.37× (vs Q4'23)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (-0.05) × ERP
WACC = 83% × Ke + 17% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 7.92 Current price: 2.80
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2013
actual 		Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
1 Rev. Ana.
1 EPS Ana. 		Dec 2027
1 Rev. Ana.
1 EPS Ana. 		Dec 2028
1 Rev. Ana.
1 EPS Ana.
Revenue
347.05M
est: 346.11M (+0.3%)
654.01M
est: 676.20M (-3.3%)
775.66M
est: 801.00M (-3.2%)
899.59M
est: 913.90M (-1.6%)
1.18B
est: 1.11B (+5.8%)
1.28B
est: 1.33B (-3.7%)
978.11M
est: 1.34B (-26.9%)
1.64B
est: 1.18B (+39.1%)
1.32B
est: 1.60B (-17.4%)
1.71B
est: 1.70B (+0.2%)
1.67B
est: 1.68B (-0.7%)
1.81B
est: 1.68B (+8.0%)
1.87B
1.87B – 1.87B
+11.4% YoY
2.13B
2.13B – 2.13B
+13.8% YoY
2.47B
2.47B – 2.47B
+16.2% YoY
EBITDA
77.73M
est: 88.29M (-12.0%)
142.92M
est: 172.49M (-17.1%)
177.47M
est: 204.33M (-13.1%)
217.36M
est: 233.13M (-6.8%)
299.87M
est: 259.68M (+15.5%)
386.15M
est: 331.60M (+16.4%)
279.50M
est: 341.31M (-18.1%)
436.65M
est: 300.29M (+45.4%)
313.54M
est: 407.16M (-23.0%)
418.38M
est: 434.59M (-3.7%)
400.71M
est: 419.72M (-4.5%)
467.90M
est: 418.97M (+11.7%)
466.88M
466.88M – 466.88M
+11.4% YoY
531.51M
531.51M – 531.51M
+13.8% YoY
617.59M
617.59M – 617.59M
+16.2% YoY
EBIT
75.11M
est: 78.49M (-4.3%)
132.71M
est: 153.34M (-13.5%)
171.92M
est: 181.64M (-5.4%)
206.55M
est: 207.25M (-0.3%)
280.46M
est: 252.23M (+11.2%)
358.73M
est: 326.25M (+10.0%)
252.28M
est: 417.30M (-39.5%)
403.68M
est: 266.95M (+51.2%)
272.01M
est: 361.95M (-24.9%)
358.87M
est: 386.34M (-7.1%)
354.79M
est: 371.96M (-4.6%)
416.78M
est: 371.30M (+12.2%)
413.76M
413.76M – 413.76M
+11.4% YoY
471.03M
471.03M – 471.03M
+13.8% YoY
547.32M
547.32M – 547.32M
+16.2% YoY
Net Income
54.90M
est: 59.40M (-7.6%)
104.90M
est: 110.64M (-5.2%)
136.28M
est: 133.93M (+1.8%)
167.30M
est: 170.79M (-2.0%)
231.09M
est: 209.64M (+10.2%)
302.50M
est: 268.82M (+12.5%)
218.93M
est: 320.28M (-31.6%)
345.97M
est: 314.45M (+10.0%)
225.41M
est: 343.57M (-34.4%)
275.26M
est: 343.57M (-19.9%)
307.22M
est: 266.50M (+15.3%)
318.09M
est: 323.20M (-1.6%)
323.20M
323.20M – 323.20M
+0.0% YoY
351.55M
351.55M – 351.55M
+8.8% YoY
419.60M
419.60M – 419.60M
+19.4% YoY
SGA
237.58M
est: 228.94M (+3.8%)
403.27M
est: 471.16M (-14.4%)
458.50M
est: 529.82M (-13.5%)
555.70M
est: 604.50M (-8.1%)
718.63M
est: 686.78M (+4.6%)
714.54M
est: 835.96M (-14.5%)
588.24M
est: 885.02M (-33.5%)
989.71M
est: 778.64M (+27.1%)
914.19M
est: 1.06B (-13.4%)
1.23B
est: 1.13B (+9.1%)
1.15B
est: 1.13B (+1.2%)
1.21B
est: 1.13B (+6.6%)
1.26B
1.26B – 1.26B
+11.4% YoY
1.44B
1.44B – 1.44B
+13.8% YoY
1.67B
1.67B – 1.67B
+16.2% YoY
EPS
0.10
est: 0.10 (-3.3%)
0.19
est: 0.19 (+0.0%)
0.24
est: 0.23 (+4.3%)
0.30
est: 0.29 (+2.3%)
0.39
est: 0.36 (+8.3%)
0.52
est: 0.50 (+4.0%)
0.38
est: 0.55 (-30.9%)
0.60
est: 0.54 (+11.1%)
0.39
est: 0.59 (-33.9%)
0.49
est: 0.59 (-16.9%)
0.54
est: 0.47 (+14.9%)
0.56
est: 0.57 (-1.8%)
0.57
0.57 – 0.57
+0.0% YoY
0.62
0.62 – 0.62
+8.8% YoY
0.74
0.74 – 0.74
+19.4% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 A+ 4/5 5/5 4/5 5/5 3/5 3/5 4/5
2026-05-28 A+ 4/5 5/5 4/5 5/5 3/5 3/5 4/5
2026-05-27 A+ 4/5 5/5 4/5 5/5 3/5 3/5 4/5
2026-05-26 A+ 4/5 5/5 4/5 5/5 3/5 3/5 4/5
2026-05-22 A+ 4/5 5/5 4/5 5/5 3/5 3/5 4/5
2026-05-21 A+ 4/5 5/5 4/5 5/5 3/5 3/5 4/5
2026-05-20 A+ 4/5 5/5 4/5 5/5 3/5 3/5 4/5
2026-05-19 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5
2026-05-18 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5
2026-05-15 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5
2026-05-14 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5
2026-05-13 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5
2026-05-12 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5
2026-05-11 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5
2026-05-08 A+ 4/5 5/5 4/5 5/5 2/5 4/5 4/5
2026-05-07 A+ 4/5 5/5 4/5 5/5 2/5 4/5 4/5
2026-05-06 A+ 4/5 5/5 4/5 5/5 2/5 4/5 4/5
2026-05-05 A+ 4/5 5/5 4/5 5/5 2/5 4/5 4/5
2026-05-04 A+ 4/5 5/5 4/5 5/5 2/5 4/5 4/5
2026-04-30 A+ 4/5 5/5 4/5 5/5 2/5 4/5 4/5
2026-04-29 A+ 4/5 5/5 4/5 5/5 2/5 4/5 4/5
2026-04-28 A+ 4/5 5/5 4/5 5/5 2/5 4/5 4/5
2026-04-27 A+ 4/5 5/5 4/5 5/5 2/5 4/5 4/5
2026-04-24 A+ 4/5 5/5 4/5 5/5 2/5 4/5 4/5
2026-04-23 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5
2026-04-22 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5
2026-04-21 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5
2026-04-20 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5
2026-04-17 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5
2026-04-16 A 4/5 5/5 4/5 5/5 2/5 3/5 4/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
556.70M
OE per share TTM
0.96
Owner's Yield
32.29%
Maintenance CapEx ratio
46.85%
Maint CapEx / Avg PPE
24.7%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 5 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 Avantis Emerging Markets Small Cap Equity ETF AVEE 0.01% 6.2K 0.42%
2 Dimensional - Emerging Markets Core Equity 2 ETF DFEM 0.00% 128.4K 0.39%
3 Avantis Emerging Markets Equity ETF AVEM 0.00% 92.6K 0.33%
4 Dimensional World ex U.S. Core Equity 2 ETF DFAX 0.00% 29.2K 0.28%
5 Dimensional - Emerging Core Equity Market ETF DFAE 0.00% 20.9K 0.29%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
287.4K
Shares Outstanding
567.01M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Mia Je Ngiam Founder & Chairman 3M —
Hian Leng Ngiam Chief Executive Officer & Executive Director 2M male
Haizhou Fang Executive Director 2M male
Lai Man Yau Executive Director & Company Secretary 763.1K female
Qi Xue Group Chief Scientific Officer — —
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Drug Manufacturers - Specialty & Generic